Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas
J. Li, C. R. Chin, H.-Y. Ying, C. Meydan, M. R. Teater, M. Xia, P. Farinha, K. Takata, C.-S. Chu, M. A. Rivas, A. Chadburn, C. Steidl, D. W. Scott, R. G. Roeder, C. E. Mason, W. Beguelin, A. M. Melnick
Abstract
Mutations affecting enhancer chromatin regulators CREBBP and KMT2D are highly co-occurrent in germinal center (GC)-derived lymphomas and other tumors, even though regulating similar pathways. Herein, we report that combined haploinsufficiency of Crebbp and Kmt2d (C+K) indeed accelerated lymphomagenesis. C+K haploinsufficiency induced GC hyperplasia by altering cell fate decisions, skewing B cells away from memory and plasma cell differentiation. C+K deficiency particularly impaired enhancer activation for immune synapse genes involved in exiting the GC reaction. This effect was especially severe at super-enhancers for immunoregulatory and differentiation genes. Mechanistically, CREBBP and KMT2D formed a complex, were highly co-localized on chromatin, and were required for each-others stable recruitment to enhancers. Notably, C+K lymphomas in mice and humans manifested significantly reduced CD8+ T-cell abundance. Hence, deficiency of C+K cooperatively induced an immune evasive phenotype due at least in part to failure to activate key immune synapse super-enhancers, associated with altered immune cell fate decisions. SIGNIFICANCEAlthough CREBBP and KMT2D have similar enhancer regulatory functions, they are paradoxically co-mutated in lymphomas. We show that their combined loss causes specific disruption of super-enhancers driving immune synapse genes. Importantly, this leads to reduction of CD8 cells in lymphomas, linking super-enhancer function to immune surveillance, with implications for immunotherapy resistance.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
Ted B. Piorczynski, Yuxuan Liu, … Jennifer Effie Amengual·bioRxiv·Mar 13, 2025
- KMT2D regulates thymic egress by modulating maturation and integrin expression
S. J. Potter, L. Zhang, … H. T. Bjornsson·bioRxiv·Oct 4, 2022
- Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
P. Mondello, S. Tadros, … M. Green·bioRxiv·Jan 27, 2019
- Mutational synergy with CREBBP loss in lymphomagenesis identified through forward insertional mutagenesis in a new DLBCL mouse model
Nathalie Sakakini, Roy Straver, … Brian J.P. Huntly·bioRxiv·Mar 25, 2024
- KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas
J. A. Heward, L. Koniali, … J. Fitzgibbon·bioRxiv·Jun 30, 2020
- Characterizing the molecular impact of KMT2D variants on the epigenetic and transcriptional landscapes in Kabuki Syndrome
Youngsook Lucy Jung, Christina Hung, … Olaf A. Bodamer·Human Molecular GeneticsPeer-reviewed·Apr 11, 2023